Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

MSTU trades at $1.87, down 1.06% with a bearish technical outlook showing 15 sell signals versus 1 buy signal. The ETF has experienced significant value erosion, with recent articles highlighting a 98% loss from November 2024 levels despite a 10:1 reverse stock split. Technical indicators show moving averages are unanimously bearish while oscillators remain neutral, with support and resistance clustered around $2.

The outlook remains challenging given the ETF's leveraged structure and substantial historical losses. Investment opportunity exists only for sophisticated traders comfortable with high volatility, while risks include daily rebalancing effects and continued erosion of value in declining markets. The fund's performance remains tightly coupled to its underlying asset's volatility.

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.